Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.

Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL.

BMC Cancer. 2007 May 19;7:85.

2.

Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation.

Crugliano T, Quaresima B, Gaspari M, Faniello MC, Romeo F, Baudi F, Cuda G, Costanzo F, Venuta S.

Int J Biochem Cell Biol. 2007;39(1):220-6. Epub 2006 Aug 30.

PMID:
17005433
3.

Expression of human protein phosphatase-1 in Saccharomyces cerevisiae highlights the role of phosphatase isoforms in regulating eukaryotic functions.

Gibbons JA, Kozubowski L, Tatchell K, Shenolikar S.

J Biol Chem. 2007 Jul 27;282(30):21838-47. Epub 2007 Jun 1.

4.

Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR.

Saunus JM, French JD, Edwards SL, Beveridge DJ, Hatchell EC, Wagner SA, Stein SR, Davidson A, Simpson KJ, Francis GD, Leedman PJ, Brown MA.

Cancer Res. 2008 Nov 15;68(22):9469-78. doi: 10.1158/0008-5472.CAN-08-1159.

5.

RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer.

Emberley ED, Gietz RD, Campbell JD, HayGlass KT, Murphy LC, Watson PH.

BMC Cancer. 2002 Nov 6;2:28.

6.

BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.

Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA, King MC.

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7560-5.

7.

Haplo-insufficiency of BRCA1 in sporadic breast cancer.

Staff S, Isola J, Tanner M.

Cancer Res. 2003 Aug 15;63(16):4978-83.

8.

BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions.

Yarden RI, Papa MZ.

Mol Cancer Ther. 2006 Jun;5(6):1396-404. Review.

9.

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J.

Breast Cancer Res Treat. 2006 Sep;99(1):85-90. Epub 2006 Mar 16.

PMID:
16541313
10.

Analysis of specific interactions of native protein phosphatase 1 isoforms with targeting subunits.

Colbran RJ, Carmody LC, Bauman PA, Wadzinski BE, Bass MA.

Methods Enzymol. 2003;366:156-75.

PMID:
14674248
11.

Proteomic characterization of protein phosphatase 1 complexes in ischemia-reperfusion and ischemic tolerance.

Cid C, Garcia-Bonilla L, Camafeita E, Burda J, Salinas M, Alcazar A.

Proteomics. 2007 Sep;7(17):3207-18.

PMID:
17683050
12.

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.

Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benítez J.

Breast Cancer Res Treat. 2005 Mar;90(1):5-14.

PMID:
15770521
13.

Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.

Walker LC, Waddell N, Ten Haaf A; kConFab Investigators, Grimmond S, Spurdle AB.

Breast Cancer Res Treat. 2008 Nov;112(2):229-36. Epub 2007 Dec 20.

PMID:
18095154
14.

BCoR-L1 variation and breast cancer.

Lose F, Arnold J, Young DB, Brown CJ, Mann GJ, Pupo GM; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Khanna KK, Chenevix-Trench G, Spurdle AB.

Breast Cancer Res. 2007;9(4):R54. Erratum in: Breast Cancer Res. 2008;10(5):406.

15.

Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.

Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H.

Clin Cancer Res. 2008 Apr 1;14(7):1976-83. doi: 10.1158/1078-0432.CCR-07-4100.

16.

The neuronal actin-binding proteins, neurabin I and neurabin II, recruit specific isoforms of protein phosphatase-1 catalytic subunits.

Terry-Lorenzo RT, Carmody LC, Voltz JW, Connor JH, Li S, Smith FD, Milgram SL, Colbran RJ, Shenolikar S.

J Biol Chem. 2002 Aug 2;277(31):27716-24. Epub 2002 May 16.

17.

Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer.

Huang CS, Shen CY, Wang HW, Wu PE, Cheng CW.

Clin Chim Acta. 2007 Sep;384(1-2):69-74. Epub 2007 Jun 15.

PMID:
17651715
18.

Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines.

Favy DA, Lafarge S, Rio P, Vissac C, Bignon YJ, Bernard-Gallon D.

Biochem Biophys Res Commun. 2000 Jul 21;274(1):73-8.

PMID:
10903898
19.

Tetratricopeptide repeat domain 9A is an interacting protein for tropomyosin Tm5NM-1.

Cao S, Ho GH, Lin VC.

BMC Cancer. 2008 Aug 12;8:231. doi: 10.1186/1471-2407-8-231.

20.

Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.

Melchor L, Honrado E, García MJ, Alvarez S, Palacios J, Osorio A, Nathanson KL, Benítez J.

Oncogene. 2008 May 15;27(22):3165-75. Epub 2007 Dec 10.

PMID:
18071313

Supplemental Content

Support Center